AngioDynamics (ANGO) Peer Comparison
$15.85
$0.07
(0.44%)
As on 28-Aug-2026 16:00EDT
Market cap
$651 Mln
Revenue (TTM)
$320 Mln
P/E Ratio
--
P/B Ratio
3.8
Div. Yield
0 %
Edit
| AngioDynamics (ANGO) | Neogen (NEOG) | Simulations Plus (SLP) | Accuray (ARAY) | ResMed (RMD) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
651 | 2,606 | 372 | 33 | 32,953 |
Revenue ($ Mln) |
320 | 870 | 82 | 402 | 5,653 |
Net Profit ($ Mln) |
-36.74 | -7.90 | 8.11 | -49.19 | 1,523.29 |
Net Margin (%) |
-11.48 | -0.91 | 9.88 | -12.24 | 26.94 |
RoE (%) |
-20.77 | -0.38 | 6.09 | -80.08 | 24.27 |
Price to Earnings |
-- | -- | 46.00 | -- | 22.11 |
Price-To-Book |
3.81 | 1.23 | 2.68 | 0.75 | 5.05 |
Income Statement ($ Mln)
| AngioDynamics (ANGO) | Neogen (NEOG) | Simulations Plus (SLP) | Accuray (ARAY) | ResMed (RMD) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
320.17 | 870.40 | -- | 401.95 | 5,653.44 |
|
Cost of Revenue
|
145.28 | 461.90 | -- | 290.49 | 2,195.77 |
|
Gross Profit
|
174.89 | 408.50 | -- | 111.45 | 3,457.68 |
|
Operating Expenses
|
214.82 | 430.10 | -- | 137.90 | 1,565.03 |
|
Operating Profit (EBIT)
|
-39.93 | -21.60 | -- | -26.44 | 1,892.65 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-36.30 | -9.00 | -- | -47.25 | 1,919.42 |
|
Provision for Tax
|
0.44 | -1.10 | -- | 1.95 | 396.12 |
|
Profit after Tax (Net Income)
|
-36.74 | -7.90 | -- | -49.19 | 1,523.29 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| AngioDynamics (ANGO) | Neogen (NEOG) | Simulations Plus (SLP) | Accuray (ARAY) | ResMed (RMD) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
170.83 | 2,092.90 | -- | 41.70 | 6,585.39 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
21.62 | 1,094.90 | -- | 210.57 | 985.45 |
|
Current Liabilities
|
74.72 | 158.20 | -- | 191.41 | 1,395.11 |
|
Total Liabilities
|
267.16 | 3,346.00 | -- | 443.68 | 8,965.95 |
Assets ($ Mln)
| AngioDynamics (ANGO) | Neogen (NEOG) | Simulations Plus (SLP) | Accuray (ARAY) | ResMed (RMD) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
103.77 | 2,741.40 | -- | 156.18 | 4,641.21 |
|
Current Assets
|
163.39 | 604.60 | -- | 287.50 | 4,324.74 |
|
Total Assets
|
267.16 | 3,346.00 | -- | 443.68 | 8,965.95 |
|
Total Debt*
|
-- | 793.70 | -- | 183.87 | 825.92 |
|
Net Current Assets
|
88.68 | 446.40 | -- | -- | -- |
Cashflow ($ Mln)
| AngioDynamics (ANGO) | Neogen (NEOG) | Simulations Plus (SLP) | Accuray (ARAY) | ResMed (RMD) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
3.09 | 83.20 | -- | -6.98 | 1,805.83 |
|
Cash Flow from Investing Activities
|
-5.95 | 70.50 | -- | -12.28 | -545.20 |
|
Cash from Financing Activities
|
0.56 | -99.40 | -- | 6.98 | -1,007.03 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| AngioDynamics (ANGO) | Neogen (NEOG) | Simulations Plus (SLP) | Accuray (ARAY) | ResMed (RMD) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-20.19 | -0.27 | -- | -20.37 | 21.41 |
|
ROE (%)
|
-20.77 | -0.38 | -- | -80.08 | 24.27 |
|
ROA (%)
|
-13.43 | -0.23 | -- | -10.77 | 17.77 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-11.48 | -0.91 | -- | -12.24 | 26.94 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| AngioDynamics (ANGO) | Neogen (NEOG) | Simulations Plus (SLP) | Accuray (ARAY) | ResMed (RMD) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
0.09 | -0.03 | -- | -0.12 | 0.10 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-8.09 | 99.28 | -- | -2,992.02 | 8.75 |
|
EPS Growth (%)
|
-- | -- | -- | -26.45 | 0.10 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| AngioDynamics (ANGO) | Neogen (NEOG) | Simulations Plus (SLP) | Accuray (ARAY) | ResMed (RMD) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | -- | -- | -0.64 | 18.55 |
|
Price / Book Value
|
-- | -- | -- | 0.76 | 4.29 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-286.51 | 3.57 | -- | -12.15 | 12.86 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| AngioDynamics (ANGO) | Neogen (NEOG) | Simulations Plus (SLP) | Accuray (ARAY) | ResMed (RMD) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-- | 0.38 | -- | 4.41 | 0.13 |
|
Short term debt to equity ratio
|
-- | -- | -- | 0.23 | 0.04 |
|
Current Ratio
|
2.19 | 3.82 | -- | 1.50 | 3.10 |
|
Quick Ratio
|
1.49 | 2.91 | -- | 0.73 | 2.42 |
|
Interest Coverage
|
-75.14 | 0.84 | -- | -- | 67.12 |
Operating Efficiency Ratios
| AngioDynamics (ANGO) | Neogen (NEOG) | Simulations Plus (SLP) | Accuray (ARAY) | ResMed (RMD) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
15.09 | 16.87 | -- | 16.77 | 18.33 |
|
Asset Turnover
|
1.17 | 0.26 | -- | 0.88 | 0.66 |
|
Receivable days
|
52.17 | 62.98 | -- | 75.09 | 65.48 |
|
Inventory Days
|
143.86 | 132.51 | -- | 181.12 | 155.82 |
|
Payable days
|
81.46 | 62.75 | -- | 46.89 | 48.83 |
|
Cash Conversion Cycle
|
114.57 | 132.75 | -- | 209.32 | 172.47 |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
